PARIS (Thomson Financial) - Pharmaceutical producer Ipsen said its first
half operating profit was 112.9 mln eur, up from 108.4 mln a year earlier, as
sales grew strongly despite a difficult environment with growing competition and
substantial price declines.
It reaffirmed the full year guidance on sales and operating margin that it
raised a month ago. Sales are seen growing by 6.5-7.5 pct, and the operating
margin is seen at 22.0-23.0 pct.
The company said the foundations for accelerating growth have been
reinforced, and promised a second half that is rich in developments, notably the
firming up of its alliance with Tercica in Europe and the expected approval of
Somatuline in the US.
tfn.paris@thomson.com
mjs/cm2
COPYRIGHT
Copyright AFX News Limited 2007. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by
framing or similar means, is expressly prohibited without the prior written
consent of AFX News.
|